| 书目名称 | Valuation in Life Sciences | | 副标题 | A Practical Guide | | 编辑 | Boris Bogdan,Ralph Villiger | | 视频video | | | 概述 | First complete guide to valuation in life sciences (pharma, biotech, medtech).Step-by-step explanation of how to practice valuation of projects and contracts.With relevant data and many real-life exam | | 图书封面 |  | | 描述 | Capital, whether it originates from venture, public equity, private, or g- ernment sources, continues to be biotech’s source of sustenance. In fact, access to financing can make or break a company, regardless of whether it has Nobel Prize winning science or a top-flight business school mana- ment team. In order to attract capital there has to be a “value proposition” that is sufficiently engaging and well constructed that will not only capture the imagination of investors but also make them want to ultimately invest. This book recognizes that there is no consent on how to apply valuation methodologies in life sciences. One of the complicating factors is that, compared to other industries, valuation of biotech innovation is much more demanding. The long 10-15-year development and clinical trials process still represents the main risks faced by any biotech company. Added to that is the fact that getting a drug across the regulatory goal line and receiving Food and Drug Administration approval (or other regulatory agency - proval in the United States or elsewhere in the world) for marketing is no longer good enough. Since the biotechnology industry is not isolated from the major influ | | 出版日期 | Book 20071st edition | | 关键词 | Biotech; Cash-flow; Computerassistierte Detektion; Medtech; Pharma; Radiologieinformationssystem; Real Opt | | 版次 | 1 | | doi | https://doi.org/10.1007/978-3-540-45567-7 | | isbn_ebook | 978-3-540-45567-7 | | copyright | Springer-Verlag Berlin Heidelberg 2007 |
The information of publication is updating
|
|
发表于 2025-3-21 17:28:22
